Frailty Assessment and Treatment Effects in Clinical Trials of Disease-Modifying Therapies for CKD
American Journal of Kidney Diseases · 2026-10
DOI: 10.1053/j.ajkd.2026.06.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Kidney Diseases, 2026-10. Verfasst von Changyuan Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Groningen Kolff Centre for Kidney Research, University Medical Center Groningen, University of Groningen, Groningen, the Ne…. Die Arbeit nennt 37 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Frailty is common in chronic kidney disease (CKD) and is independently associated with disability and mortality. However, evidence on the optimal treatment of frail adults with CKD remains limited. Consequently, regulators have encouraged routine assessment of frailty and the reporting of outcomes stratified by frailty in clinical studies. In this narrative review, we found that several recent clinical trials of disease-modifying therapies for CKD evaluated treatment effects across frailty strata and reported consistent benefits, with potentially greater benefits in the highest frailty subgroup. However, frailty was not formally assessed in any of these trials, and the proxy measures used may not have fully captured the multidimensional aspects of frailty needed to inform treatment decisions.
Autor:innen und Institutionen
- Department of Nephrology, Groningen Kolff Centre for Kidney Research, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- East Hospital, Tongji University School of Medicine, Shanghai, China.
- Division of Health, University of Waikato, Hamilton, New Zealand.
- Vanderbilt University Medical Center, Division of Nephrology and Hypertension, Nashville, TN; Tennessee Valley Veterans Affairs Health System, Geriatric Research Education and Clinical Center, Nashville, TN; Veteran Wel…
- Department of Clinical Pharmacy and Pharmacology, Groningen Kolff Centre for Kidney Research, University Medical Center Groningen, University of Groningen, Groningen, Groningen, the Netherlands.
Zitieren
APA
Yang, C., Chen, D., Chepulis, L., Nair, D., & Vart, P. (2026). Frailty Assessment and Treatment Effects in Clinical Trials of Disease-Modifying Therapies for CKD. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2026.06.032
Vancouver
Yang C, Chen D, Chepulis L, Nair D, Vart P. Frailty Assessment and Treatment Effects in Clinical Trials of Disease-Modifying Therapies for CKD. American Journal of Kidney Diseases. 2026. doi:10.1053/j.ajkd.2026.06.032
BibTeX
@article{Yang2026,
author = {Yang, Changyuan and Chen, Da and Chepulis, Lynne and Nair, Devika and Vart, Priya},
title = {Frailty Assessment and Treatment Effects in Clinical Trials of Disease-Modifying Therapies for CKD},
journal = {American Journal of Kidney Diseases},
year = {2026},
doi = {10.1053/j.ajkd.2026.06.032}
}
EUVIMED